ArticleWomen's health (London, England)2016
Breast cancer subtypes: morphologic and biologic characterization.
Article in Women's health (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Grade III canine and feline mammary carcinomas are associated with an immunosuppressed, vascularized and proliferative microenvironment.BMC veterinary research · 2026Article
- Inflammatory Proteins Mediate the Causal Association between Sleep Traits and Breast Cancer: A Mendelian Randomization Study.Lifestyle genomics · 2026Article
- Trastuzumab-Conjugated pH-Sensitive Micelles Exhibit Antitumor Activity and Induce Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer Cell Lines.Pharmaceutics · 2025Article
- Insights into the molecular and genetic role of obesity in breast cancer pathogenesis.Cancer biology & therapy · 2025Review
- Adenoid cystic carcinoma of the breast with aggressive behavior: A case report and review of the literature.Oncology letters · 2025Article
- Assessment of Immunohistochemical Expression of Cluster of Differentiation 44 (CD44) in Breast Carcinoma.Cureus · 2025Article
- Associations Between Lipid Traits and Breast Cancer Risk: A Mendelian Randomization Study in African Women.Cancer medicine · 2025Article
- Relevance of Cellular Homeostasis-Related Gene Expression Signatures in Distinct Molecular Subtypes of Breast Cancer.Biomedicines · 2025Article
- Molecular Classification of Breast Cancer Using Weakly Supervised Learning.Cancer research and treatment · 2025Article
- Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients.Breast cancer research : BCR · 2024Article
- Precision medicine in breast cancer (Review).Molecular and clinical oncology · 2024Review
- Understanding genetic variations associated with familial breast cancer.World journal of surgical oncology · 2024Review
- Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes.Cellular and molecular life sciences : CMLS · 2024Article
- Associations amongst genes, molecules, cells, and organs in breast cancer metastasis.Clinical & experimental metastasis · 2024Review
- Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.Cancers · 2024Review
- Exploring the antitumor potential of novel quinoline derivativesRSC advances · 2024Article
- Article
- Shear Wave Elastography in Breast Cancer: Unveiling Correlations With Histopathological Grades and Subtypes.Cureus · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in basic science, technology and translational research have created a revolution in breast cancer diagnosis and therapy. Researchers' discoveries of genes defining variability in response to therapy and heterogeneity in clinical presentations and tumor biology are the foundation of the path to personalized medicine. The success of personalized breast cancer care depends on access to pertinent clinical information and risk factors, optimal imaging findings, well-established morphologic features, and traditional and contemporary prognostic/predictive testing. The integration of these entities provides an opportunity to identify patients who can benefit from specific therapies, and demonstrates the link between breast cancer subtypes and their association with different tumor biology. It is critical to recognize specific types of breast cancer in individual patients and design optimal personalized therapy. This article will highlight the roles of morphologic features and established tumor biomarkers on patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.